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Can bone marrow mesenchymal stem 
cells regenerate the myocardium?
ABSTRACT
Background: Cardiovascular diseases are the serious clinical problem, especially the loss of viable my-
ocytes. A new approach, which provides a novel method for the treatment, is a tissue engineering and 
regenerative medicine. One of the current cell types used as a source to improve cardiac tissue repair, 
are MSCs. The aim of this study was to check if the 5’azacitidine and growth factors from cardiomyocyte 
cell line initiate the differentiation of MSCs toward cardiomyocytes. 
Material and methods: Bone marrow MSCs were isolated and their biological features have been char-
acterized. Conditioned media were prepared with the use of 5’azacitidine and growth factors released 
from cardiomyocytes.
Results: The transdifferentiating process has been confirmed by the expression of specific muscle markers. 
Conditioned medium from cardiomyocyte cell line, as well as, 5’azacitidine induced muscle differentiation 
process in bone marrow MSCs in comparison to the control. 
Conclusions: Presented in this study data support the conclusion that this concept may represent a prom-
ising strategy for the repair of cardiac tissue, however, further experiments are necessary.
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Introduction
Cardiovascular diseases are the leading cause of 
death worldwide [1]. Despite improvements in surviv-
al rates following myocardial infarction, reduction in 
cardiac function attributable to the irreversible loss of 
viable myocytes remains a major clinical problem [2]. 
Unfortunately, the only therapy available to reverse 
the decline in cardiac function is heart transplantation. 
However, this option is available to very few patients 
due to a shortage of donor hearts [3]. Newly emerging 
technology, which may provide a  novel method for 
the treatment of cardiovascular diseases, is regener-
ative medicine. Stem cell transplantation is a potential 
approach to repopulate injured myocardium, to treat 
heart failure and restore cardiac function [1]. A variety 
of cell types have been examined for their potential to 
achieve this type of cardiac reconstitution, but few have 
been shown to differentiate into myocytes capable of 
connecting with residual cardiomyocytes both mechan-
ically and electrically following implantation [4]. Bone 
marrow Mesenchymal Stem Cells (MSCs) are one of the 
current cell types being studied as a source of factors 
to improve tissue repair [5]. Autologous MSCs are ca-
pable of differentiating into adipogenic, chondrogenic, 
osteogenic, and myogenic cell lines [1, 6]. The relatively 
wide range of differentiation, coupled with high prolifer-
ation rate and relative ease of isolation, has made these 
cells suitable candidates for heart failure autologous 
cell therapy applications. The success of such therapy 
depends on the ability of stem cells transdifferentiation 
into cardiomyocytes in vitro and in vivo.
The aim of this study was to create conditions mim-
icking cardiomyoblasts environment. We have checked 
how 5’azacitydyne and growth factors from cardiomyo-
cyte cell line influenced on transdifferentiation of bone 
marrow mesenchymal stem cells into cardiomyocytes 
phenotype. 
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Materials and methods
Isolation and culture of bone marrow 
mesenchymal stem cells
Rat bone marrow mesenchymal stem cells were 
isolated according to a protocol modified from Lennon 
and Caplan [7]. Briefly, bone marrow was collected by 
flushing femurs with complete medium. Cells were then 
washed and centrifuged twice in PBS (PAA, Austria), 
plated in Petri dishes and cultivated in 37°C. After 3 days, 
nonadherent cells were removed and adherent cells 
were further cultured in complete medium for 14 days. 
Basic culture medium for rat bone marrow mes-
enchymal stem cells was prepared containing 
DMEM/Ham’s F12 (PAA, Austria) supplemented with 
10% FBS (PAA, Austria), 10 ng/ml bFGF (Sigma, 
Germany), 5 µg/ml amphotericin B (PAA, Austria) and 
100 µg/ml penicillin/streptomycin (PAA, Austria). 
The phenotype of mesenchymal stem cells was 
confirmed by colony forming efficiency assay and ad-
ipogenic and osteogenic assay. Briefly, for single cell 
approaches, equal numbers of isolated mesenchymal 
stem cells (5x103 cells/cm2) were plated in six-well 
culture plates. After 14 days of culture stem cell, colo-
nies were visualized by staining with 2% rhodamine B 
(Sigma, Germany). The colony forming efficiency (CFE) 
was calculated using the following formula: numbers of 
colonies formed/number of cells plated x 100%. 
Adipogenic differentiation was induced by add-
ing the following reagents to the cell medium: 
DMEM/Ham’s F12 (3:1) containing 10% FBS, 10 µM 
insulin (Sigma, Germany), 1 µM dexamethasone (Sig-
ma, Germany), 5 µg/ml amphotericin B and 100 µg/ml 
penicillin/streptomycin. Osteogenic differentiation was 
induced by the use of DMEM/Ham’s F12 (3:1) medium 
containing 15% FBS, 50 µM ascorbic acid (Sigma, 
Germany), 0.1 µM dexamethasone, 5 µg/ml ampho-
tericin B and 100 µg/ml penicillin/streptomycin. Cells 
in both media were cultivated at 37°C in a humidified 
atmosphere with 5% CO2 for 16 days.
The culture of immortalized cardiomyocyte cell line 
Culture medium for immortalized cardiomyocyte cell 
line H9C2 (ATCC, USA) contained DMEM/Ham’s F12, 
supplemented with 10% FBS, 5 µg/ml amphotericin B 
and 100 µg/ml penicillin/streptomycin. The harvested 
medium was designated conditioned media, filtered 
and stored at -80°C until use.
Flow cytometry analysis of bone marrow 
mesenchymal stem cells 
C D 9 0  ( 1 0  µ / t e s t ,  C h e m i c o n ,  U K )  a n d 
CD34 (1 µg/1x106 cell, Santa Cruz, USA) were used 
to characterize the primary cultures by flow cytometry. 
Cells were resuspended at a density of 1x106 cells/ml 
in cold PBS containing antibodies connected with 
FITC or phycoerythrin (Sigma, Germany). Labelling 
reaction was incubated in the dark for 30 min. at 4°C. 
After cells were washed three times and centrifuged, 
flow cytometry analysis was performed on a  EPICS 
XL flow cytometry using System 2 Software Version 
3.0 (Beckman-Coulter, Miami FL, USA).
Conditioning of mesenchymal stem cell culture 
system with 5’azacitydyne
MSCs basic culture medium was supplemented 
with 10 µmol/l 5’azacitydyne (Sigma, Germany). MSCs 
were pre-incubated in medium with 5’azacitydyne for 
24 hours. After that time, the medium was removed and 
MSCs were subcultivated for 14 days in basic medium.
Conditioning of mesenchymal stem cell culture 
system with growth factors released from 
cardiomyocyte cell line
Mesenchymal stem cells from bone marrow were 
clonally enriched. After 14 days of cultivation, cells were 
trypsinized with 0.25% Trypsin-EDTA (PAA, Austria). 
Clonal cells were seeded at a density of 5x103 cells onto 
18mm cover glasses (Witko, Poland) and placed into 
twelve-well culture plates. After 24 hours of pre-incuba-
tion, the basic medium was removed and mesenchymal 
stem cells were subcultivated for another 14 days in 
conditioned media obtained from the immortalized 
cardiomyocyte cell line.
Fluorescence immunostaining as a detection tool 
for transdifferentiation
For immunolabeling of cell sheets, clonal cells 
were plated onto cover glasses (Witko, Poland) and 
cultivated under various environmental conditions, 
such as 5’azacitydyne and conditioned medium for 
14 days. After cultivation time, cells were fixed with 4% 
paraformaldehyde in PBS (pH 7.4) at room temperature 
for 20 min., washed with PBS (3x5 min) and blocked 
with 0.1 M glycine for 10 min. Permeabilization was 
performed by incubation with 0.25% Triton X-100 in 
PBS for 10 min. After incubation with 1% bovine serum 
albumin (BSA, Sigma, Germany) for 30 min, cells were 
stained with rat-specific primary antibodies against 
calponin, a-actin, sarcomeric actin, myogenin (1:100, 
Abcam, UK) and desmin (1:20, Abcam, UK) for 1h at 
room temperature. Antibody binding was detected by 
TRITC-conjugated secondary antibodies (1:85, Sigma, 
Germany). Cell nuclei were labelled with DAPI (4’,6’-di-
amino-2-phenylindole, Sigma, Germany). Finally, cov-
erslips were rinsed three times with PBS for 5 min and 
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mounted in Aqua-Poly/Mount (Polysciences, Germany) 
prior to observation by using Nikon C1 laser-scanning 
microscope (Nikon, Japan). In negative control exper-
iments, 1% PBS-BSA or equimolar concentrations of 
an irrelevant primary antibody replaced the primary 
antibody. Slides were examined by two independent 
observers and then images were captured using 
EZ-C1 software (Ver. 3.80; Nikon Instruments, USA). 
Specific markers expression was evaluated using the 
semiquantitative IRS scale (0–12 points), according 
to Remmele and Stegner, which considered both the 
intensity of the colour reaction (as marker of the level 
of antigen amount) and the percentage of positive 
cells. Terminal values from 1 to 2 indicate the low in-
tensity of reaction, from 3 to 4 medium, while from 6 to 
12 high intensity of the reaction. Each experiment was 
done in triplicate.
Results
Characteristic of bone marrow mesenchymal stem 
cells
Bone marrow mesenchymal stem cells propagated 
rapidly in vitro and constituted a  homogenous fibro-
blast-like morphology (Fig. 1A). For phenotypic charac-
terization, mesenchymal stem cells were assessed for 
the expression of CD90, CD34 and CD44. The putative 
stem cell markers CD90 and CD44 which have been 
previously reported to be expressed in the rat bone mar-
row mesenchymal stem cells at high-level Karaoz et al. 
[8], were confirmed to be strongly expressed (Fig.1B). 
Staining for CD34 was negative, only single cells were 
CD34+ (Fig.1B), which indicates the mesenchymal 
nature of isolated cells. The colony forming efficiency 
(CFE), which is considered to correlate with the number 
of stem cells, was calculated to be 0.22%. Rat mesen-
chymal stem cells formed on average 11 ± 2 colonies 
(Fig. 1D). Clonal cells could be serially cultivated up to 
4 passages before they revealed signs of senescence, 
the activity of beta-galactosidase (Fig. 1C). Additionally, 
adipogenic and osteogenic differentiation of MSCs was 
performed to confirm the multipotential properties of 
isolated bone marrow MSCs (Fig. 1E–F). 
Effect of environmental conditions on the 
differentiation of bone marrow mesenchymal stem 
cells
The effect of 5’azacitydyne and cardiomyocyte 
cell line conditioned medium on calponin, a-actin, 
desmin, sarcomeric actin and myogenin expression 
was analyzed by immunofluorescence of clonal 
cells subcultivated in cover glasses. As expected, all 
muscle-specific markers appeared in mesenchymal 
stem cells due to the process of differentiation, but 
proportion of immunopositive cells showed significant 
differences depending on condition used. Conditioned 
medium from cardiomyocyte cell line (H9C2), as well as, 
5’azacitydyne supplemented medium induced muscle 
differentiation process in bone marrow mesenchymal 
stem cells in comparison to the control (mesenchy-
mal stem cells cultured alone) (Fig. 2A). Expression 
of desmin, a-actin, sarcomeric actin and myogenin 
significantly increased after 14 days of bone marrow 
mesenchymal stem cells cultivation in 5’azacitydyne 
and H9C2 conditioned media (8, 12, 3, 2 and 4, 12, 4, 
6 points, respectively, in IRS scale) (Fig. 2B–C).
Discussion 
The injured human myocardium possesses a limited 
regenerative potential. Following acute myocardial in-
farction, tissue repair is deficient and irreplaceable loss 
of cardiac muscle overloads the surviving myocardium 
resulting in heart failure or death [9]. Despite many 
breakthroughs in cardiovascular medicine, current 
therapies for heart failure are of limited benefit in re-
gaining lost cardiac function. Recently, cell therapy has 
emerged as an attractive therapeutic modality to repair 
damaged myocardium. Bone marrow mesenchymal 
stem cells are attractive for cell therapy, as they can 
give rise to various cell types, including cardiomyocytes, 
endothelial cells, and smooth muscle cells [10–12]. 
However, it is impossible to predict the differentiation 
pathway of implanted undifferentiated cells [13]. To 
reduce all side effects, the in vitro initiation of MSCs 
differentiation into cardiomyocytes can be performed 
but it can change stem cell properties. Moreover, it is 
well documented that implantation of differentiated 
into cardiomyocytes MSCs improves the function and 
regeneration of heart [14–16]. The possibility of the 
influence of neighbouring cardiomyocytes on MSCs 
differentiation is very interesting issue, as well. 
Stem cells incubated with 5’azacitydyne changed 
their phenotype toward cardiomyocytes [17–19]. Tomita 
and coworkers [20] stated that 10µM 5’azacitydyne, 
added for 24 hours to in vitro culture, induced differen-
tiation of mesenchymal stem cells. They also observed 
the creation of myotubule-like structures after 4 weeks 
from differentiation initiating. In our study in the same 
concentration of 5’azacitydyne we observed a strong 
expression of a-actin and desmin, which are the early 
differentiation markers, and weaker expression of sar-
comeric actin and myogenin. The gained results can 
be considered as reliable in comparison to results Xu 
et al. [21]. We did not examine the potential of cells 
to spontaneous contraction. Nevertheless, we cannot 
exclude the differentiation of MSCs towards cardiomy-
ocytes phenotype. Data concerning the differentiation 
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of stem cells by 5’azacitydyne influence are conflicting. 
Liu and coworkers [22] did not observe differentiation 
of rat bone marrow mesenchymal stem cells in cardio-
myocytes with use of 3, 5 and 10µM of 5’azacitydyne 
while Xu and coworkers had done [21]. The most 
probably, additional factors are required for successful 
cardiomyocytes differentiation process. 
Experimental settings with the use of 5’azacitydyne 
are totally artificial. Such conditions do not reflect any 
aspect of the environment within native heart muscle 
tissue. That is why in our study we tried to find agents 
that control differentiation process towards cardio-
myocyte lineage in the environment mimicking in vivo 
condition. We checked how conditioned medium influ-
ences on MSCs differentiation. After 14 days of culture 
in medium obtained from immortalized cardiomyocytes 
cell line, the transdifferentiation process was observed. 
Morphology of MSCs has been changed into muscle 
phenotype. Expression of specific muscle markers such 
as desmin, a-actin, sarcomeric actin and myogenin 
appeared following incubation with conditioned media. 
All observations support the evidences for the induc-
tion of transdifferentiation toward muscle phenotype. 
Expression of sarcomeric actin and myogenin was at 
medium and high level (4 and 6 points, respectively, 
in IRS scale). These results are in opposite to Wang 
and coworkers [23] who stated that cell fusion was 
responsible for differentiation. We proved that condi-
tioned medium has an influence on changes of MSCs 
phenotype. We think that the differentiation process is 
induced by signals from cardiomyocytes, which release 
paracrine factors.
It was noticed that the ageing process could be 
visible after a  few passages of MSCs. The aim of 
Figure 1. Evaluation of rat mesenchymal stem cells isolated from bone marrow: morphology in vitro (A), expression of 
CD90 and CD34 (B), aging process assay; b-galactosidase activity detection (C), clonogenity assay; rhodamine B staining 
indicates good visible red colonies (D), adipogenic assay; oil red staining (E), osteogenic assay; von Kossa test (F)
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transplanted stem cells is not only temporary muscle 
tissue regeneration but also replenishment of stem 
cell population to sustain the effect of treatment. The 
important question focuses on the ageing of cells used 
in the long-term effect of therapy. It is also still not 
known whether a  single or multiply injections would 
be sufficient to bring a stable functional improvement 
over a long time due to homing mechanisms are not 
well defined [24–28]. Another issue that needs to be 
considered is the number of cells delivered at the site 
of engraftment and the prevention of possible ageing 
process of injected cells [25].
Conclusions
Stem cells therapy of myocardium infarction offers 
the possibility to reconstruct the heart tissue. Our study 
shows that conditioned medium provides the inductive 
signals to initiate transdifferentiation of bone marrow 
mesenchymal stem cells cardiomyocytes-like pheno-
type. The presented data support the conclusion that 
this therapeutic concept may represent a  promising 
strategy for the repair and reconstruction of the heart 
tissue, however performing further experiments with 
co-culture of MSCs and cardiomyocytes are necessary. 
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